Biohaven Pharmaceutical announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has achieved targeted therapeutic exposures and that the compound will advance into a Phase 2 trial to evaluate efficacy for the acute treatment of migraine. BHV-3500 is a novel, third generation calcitonin gene-related peptide receptor antagonist being developed by Biohaven.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.